Skip to main content
×
×
Home

Glutamate and psychiatric disorders

  • Eva M. Tsapakis and Michael J. Travis
Extract

Most of the excitatory neurotransmission in the central nervous system (CNS) is mediated by the endogenous excitatory amino acids (EAAs) glutamate, aspartate and homocysteine. Most of the endogenous inhibitory neurotransmission is mediated by gamma-aminobutyric acid (GABA). EAAs modulate the firing of almost all neurons in the CNS, as excitatory neurotransmission can result in both neuronal inhibition and excitation. The glutamate system is the best characterised of the EAA systems (Box 1).

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Glutamate and psychiatric disorders
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Glutamate and psychiatric disorders
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Glutamate and psychiatric disorders
      Available formats
      ×
Copyright
References
Hide All
Aghajanian, G. K. & Marek, G. J. (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews, 31, 302312.
Anand, A., Charney, D. S., Oren, D. A. et al (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Archives of General Psychiatry, 57, 270276.
Andreasen, N. C., Arndt, S., Alliger, R. et al (1995) Symptoms of schizophrenia. Methods, meanings, and mechanisms. Archives of General Psychiatry, 52, 341351.
Anis, N. A., Berry, S. C., Burton, N. R. et al (1983) The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. British Journal of Pharmacology, 79, 565575.
Berman, R. M., Cappiello, A., Anand, A. et al (2000) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47, 351354.
Boyer, P. A., Skolnick, P. & Fossom, L. H. (1998) Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridisation study. Journal of Molecular Neuroscience, 10, 219233.
Bressan, R. A. & Pilowsky, L. S. (2000) Imaging the glutamatergic system in vivo – relevance to schizophrenia. European Journal of Nuclear Medicine, 27, 17231731.
Calabrese, J. R., Bowden, C. L., Sachs, G. S. et al (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Journal of Clinical Psychiatry, 60, 7988.
Carlsson, A., Hansson, L. O., Waters, N. et al (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sciences, 61, 7594.
Carlsson, A., Hansson, L. O., Waters, N. et al (1999) A glutamatergic deficiency model of schizophrenia. British Journal of Psychiatry 174 (suppl. 37), 26.
Carlsson, A., Waters, N., Holm-Waters, S. et al (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Reviews of Pharmacology and Toxicology, 41, 237260.
Davis, M., Rainnie, D. & Cassell, M. (1994) Neurotransmission in the rat amygdala related to fear and anxiety. Trends in Neurosciences, 17, 208214.
Farber, N. B., Hanslick, J., Kirby, C. et al (1998) Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology, 18, 5762.
Goff, D. C. & Wine, L. (1977) Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research, 27, 157168.
Goff, D. C., Tsai, G., Levitt, J. et al (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56, 2127.
Grotta, J., Clark, W., Coull, B. et al (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischaemic stroke. Results of a phase IIa randomised trial. Stroke, 26, 602605.
Hansson, L. O., Waters, N., Winblad, B. et al (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortem brain tissue. Journal of Neural Transmission, 98, 217235.
Heresco-Levy, U., Javitt, D. C. & Ermilov, M. (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms. Archives of General Psychiatry, 56, 2936.
Javitt, D. C. & Zukin, S. R. (1991) Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 13011308.
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y. et al (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry, 48, 627640.
Krystal, J. H., Karper, L. P., Seibyl, J. P. et al (1994) Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199214.
Krystal, J. H., Abi-Dargham, A., Laruelle, M. et al (1999a) Pharmacologic model of psychoses. In Neurobiology of Mental Illness (eds Charney, D. S., Nestler, E. & Bunney, B. S.) pp. 214224. New York: Oxford University Press.
Krystal, J. H., D'Souza, D. C., Karper, L. P. et al (1999b) Interactive effects of subanaesthetic ketamine and haloperidol. Psychopharmacology, 145, 193204.
Krystal, J. H., D'Souza, D. C., Sanacora, G. et al (2001) Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Medical Clinics of North America, 85, 559577.
Laruelle, M., Abi-Dargham, A., van Dyck, C. H. et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93, 92359240.
Leveque, J.-C., Macias, W., Rajadhyasksha, A. et al (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. The Journal of Neuroscience, 20, 40114020.
Marek, G. J., Wright, R. A., Schoepp, D. D. et al (2000) Physiological antagonism between 5-hydroxy-tryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics, 292, 7687.
Martin, P., Waters, N., Schmidt, C. J. et al (1998) Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. Journal of Neural Transmission, 105, 365396.
Meador-Woodruff, J. H. & Healy, D. J. (2000) Glutamate receptor expression in schizophrenic brain. Brain Research – Brain Research Reviews, 31, 288294.
Moghaddam, B., Adams, B., Verma, A. et al (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience, 17, 29212927.
Moghaddam, B. & Adams, B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 281, 13491352.
Morgan, C. A. R., Grillon, C., Southwick, S. M. et al (1995) Fear-potentiated startle in post-traumatic stress disorder. Biological Psychiatry, 38, 378385.
Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V. et al (1999) Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology, 20, 106118.
Olney, J. W., Wozniac, D. F. & Farber, N. B. (1997) Excitotoxic neurodegeneration in Alzheimer's disease: new hypothesis and new therapeutic strategies. Archives of Neurology, 54, 12341240.
Paul, I. A., Nowak, G., Layer, R. T. et al (1994) Adaptation of N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics, 269, 95102.
Pilowsky, L. S., Costa, D. C., Ell, P. J. et al (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I-IBZM SPET study. Psychological Medicine, 23, 791797.
Schoepp, D. D., Jane, D. E. & Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 38, 14311476.
Tamminga, C. A. (1998) Schizophrenia and glutamate. Critical Reviews in Neurobiology, 12, 2136.
Tamminga, C. A., Thaker, G. K., Buchanan, R. et al (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry, 49, 522530.
Tekin, S., Aykut-Bingol, C., Tanridag, T. et al (1998) Antiglutamatergic therapy in Alzheimer's disease: effects of lamotrigine. Journal of Neural Transmission, 105, 295303.
Tsai, G., Yang, P., Chung, L. C. et al (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 44, 10811089.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 1355-5146
  • EISSN: 1472-1481
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 24 *
Loading metrics...

Abstract views

Total abstract views: 236 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 21st April 2018. This data will be updated every 24 hours.

Glutamate and psychiatric disorders

  • Eva M. Tsapakis and Michael J. Travis
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *